Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>EGFR</i> point mutation in non‐small cell lung cancer is occasionally accompanied by a second mutation or amplification

9 Jun 2006

Abstract excerpt

Activating mutations of EGFR are found frequently in a subgroup of patients with non-small cell lung cancer (NSCLC) and are highly correlated with the response to gefitinib and erlotinib. In the present study, we searched for mutations of EGFR, HER2 and KRAS in 264 resected primary NSCLC from Japanese patients and determined whether there is a correlation between genetic alterations of these genes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to HER2/EGFR in Cancer Research
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16863509
DOI: 10.1111/j.1349-7006.2006.00233.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>EGFR</i> point mutation in non‐small cell lung cancer is occasionally accompanied by a second mutation or amplificationPMID 16863509Read ↗

[Clinical Features of EGFR Double Mutation in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Compound<i>EGFR</i>mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinomaSemantic proximity Read ↗

[EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance].Semantic proximity Read ↗

Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patientsSemantic proximity Read ↗

Analysis of <i>Epidermal Growth Factor Receptor</i> Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to GefitinibSemantic proximity Read ↗

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.Semantic proximity Read ↗

Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.Semantic proximity Read ↗

Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.Semantic proximity Read ↗

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibSemantic proximity Read ↗

Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.Semantic proximity Read ↗

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.